Incyte | INCY - Ebitda


Incyte reported $367.97M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agenus USD -10.11M 19.02M Mar/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Exelixis USD 258.29M 15.43M Mar/2026
Gilead Sciences USD 3.02B 1.01B Dec/2025
Incyte USD 367.97M 46.53M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 6.3B 2.09B Dec/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 5.3B 530M Mar/2026
Novartis USD 5.84B 235M Sep/2025
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026